AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6527988 — intervention group
Group type: COMPARATOR
Intervention: Minimal warning
Number of subjects: 0
Study 6527988 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling among normal PFT subjects
Number of subjects: 0
Study 6527988 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling among abnormal PFT subjects
Number of subjects: 0
Study 6527988 — intervention group
Group type: COMPARATOR
Intervention: Minimal warning among normal PFT subjects
Number of subjects: 0
Study 30716613 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + AAMT
Number of subjects: 105
Study 30716613 — intervention group
Group type: COMPARATOR
Intervention: TAU + Sham
Number of subjects: 105
Study 30187504 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 42
Study 30187504 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 42
Study 30187504 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 42
Study 27768792 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant (4 monthly)
Number of subjects: 48
Study 27768792 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (monthly, pro re nata)
Number of subjects: 48
Study 24352752 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 28
Study 24352752 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 28
Study 23036921 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 3g per os
Number of subjects: 286
Study 23036921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 20676837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding complications
Number of subjects: 331
Study 20676837 — intervention group
Group type: COMPARATOR
Intervention: No bleeding complications
Number of subjects: 331
Study 20676837 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated troponin level
Number of subjects: 331
Study 17309342 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate/lamivudine/zidovudine
Number of subjects: 0
Study 17309342 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor-based regimens (e.g., indinavir)
Number of subjects: 0
Study 17309342 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-based regimens
Number of subjects: 0
Study 16392280 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 150
Study 16392280 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 150
Study 16392280 — intervention group
Group type: COMPARATOR
Intervention: Control group (without beta‐blockers)
Number of subjects: 150
Study 12356784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine (3 grams per hour for 10 hours)
Number of subjects: 6
Study 10447630 — intervention group
Group type: EXPERIMENTAL
Intervention: Type VI collagen expression in arthrofibrotic tissue
Number of subjects: 13
Study 10447630 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic analysis of arthrofibrotic tissue
Number of subjects: 13
Study 10447630 — intervention group
Group type: COMPARATOR
Intervention: Comparison with normal synovial tissue
Number of subjects: 13
Study 7787408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-enriched glucose-insulin-potassium infusion (group A)
Number of subjects: 44
Study 7787408 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 44
Study 2338694 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (42 minutes, three times a week for 12 weeks, intensity 60‐70% of heart rate reserve)
Number of subjects: 10
Study 2338694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 10
Study 375436 — intervention group
Group type: EXPERIMENTAL
Intervention: Butriptyline
Number of subjects: 0
Study 375436 — intervention group
Group type: COMPARATOR
Intervention: Conventional antacid therapy
Number of subjects: 0
Study 375436 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger ulcers
Number of subjects: 0
Study 31793171 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718 (200 mg) coadministered with Rosuvastatin (10 mg)
Number of subjects: 12
Study 31793171 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718 (200 mg) as tablets
Number of subjects: 12
Study 31793171 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718 (200 mg) tablets after high-fat breakfast
Number of subjects: 12
Study 31793171 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718 (200 mg) once-daily
Number of subjects: 12
Study 31793171 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718
Number of subjects: 12
Study 30653422 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCT/AHCT + len
Number of subjects: 758
Study 30653422 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCT + RVD + len
Number of subjects: 758
Study 30653422 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCT + len
Number of subjects: 758
Study 28537583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced n-6:n-3 LCPUFA ratio diet (1.2g n-3 LCPUFA with AA-balanced diet from 15th week of gestation to 4 months postpartum)
Number of subjects: 119
Study 28537583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced n-6:n-3 LCPUFA ratio diet
Number of subjects: 119
Study 28537583 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cord blood concentrations of docosahexaenoic acid, eicosapentaenoic acid, and AA
Number of subjects: 119
Study 28537583 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 119
Study 25179768 — intervention group
Group type: EXPERIMENTAL
Intervention: TRO40303
Number of subjects: 163
Study 25179768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 23324408 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg orally QID
Number of subjects: 30
Study 23324408 — intervention group
Group type: COMPARATOR
Intervention: Neomycin 1 g orally QID
Number of subjects: 30
Study 20663992 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 221 (3, 30, or 100 mg)
Number of subjects: 55
Study 20663992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19846683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environments (MSSE)
Number of subjects: 0
Study 17075375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV)
Number of subjects: 40
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (Aleve)
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Advil)
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (Tylenol)
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 60
Study 15584488 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen and Ibuprofen
Number of subjects: 60
Study 15584488 — intervention group
Group type: EXPERIMENTAL
Intervention: All three medications
Number of subjects: 60
Study 11710407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 ml of distilled water (trial 2)
Number of subjects: 11
Study 11710407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 ml of Gatorade (trial 3)
Number of subjects: 11
Study 11710407 — intervention group
Group type: COMPARATOR
Intervention: No fluid (trial 1)
Number of subjects: 11
Study 9280886 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60
Study 9280886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 60
Study 8000803 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% red cell suspension with diluted commercial sera hyperimmune to Salmonellae and Yersinia, serovars O3 and O9
Number of subjects: 0
Study 3571772 — intervention group
Group type: EXPERIMENTAL
Intervention: L-649,923 (1000 mg)
Number of subjects: 8
Study 3571772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29629731 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (n=8)
Number of subjects: 24
Study 29629731 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (n=16)
Number of subjects: 24
Study 29629731 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone and Spironolactone
Number of subjects: 24
Study 27739263 — intervention group
Group type: EXPERIMENTAL
Intervention: Carica papaya leaf extract capsule (500 mg once daily for 5 days)
Number of subjects: 0
Study 27739263 — intervention group
Group type: COMPARATOR
Intervention: Routine supportive treatment
Number of subjects: 0
Study 23975179 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cytarabine and anthracycline with risk-adapted remission induction regimen (7+3)
Number of subjects: 795
Study 22568647 — intervention group
Group type: EXPERIMENTAL
Intervention: ALEXIS wound retractor
Number of subjects: 34
Study 22568647 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound protection
Number of subjects: 34
Study 20731651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 31
Study 20731651 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Pulsed Diode Laser (LPDL)
Number of subjects: 31
Study 20731651 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL) and Long-Pulsed Diode Laser (LPDL)
Number of subjects: 31
Study 19035420 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist working splint
Number of subjects: 33
Study 19035420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no splint)
Number of subjects: 33
Study 19035420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsplinted grip strength
Number of subjects: 33
Study 19035420 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional ability (measured using the Disabilities of the Arm, Shoulder, and Hand questionnaire and the short version of the Sequential Occupational Dexterity Assessment)
Number of subjects: 33
Study 15604591 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin monotherapy (37.5 mg/m² on days 1 + 2 of 4-week schedules)
Number of subjects: 21
Study 15604591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/Ifosfamide/5-Fluorouracil (PIF) regimen (Cisplatin same as above, Ifosfamide 2 g/m², Mesna 0.5 g/m², 5-Fluorouracil 500 mg/m², Folinic acid 30 mg/m² on days 1 + 2, all on 4-week schedules)
Number of subjects: 21
Study 12441265 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5‐fluorouracil)
Number of subjects: 348
Study 12441265 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 348
Study 10627742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully cemented stem
Number of subjects: 12
Study 10627742 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximally cemented stem
Number of subjects: 12
Study 9389673 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent ERCP within 72 hours after the beginning of pain
Number of subjects: 100
Study 9389673 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ERCP only if biliary sepsis or obstructive jaundice occurred)
Number of subjects: 100
Study 1914053 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg (n = 31)
Number of subjects: 92
Study 1914053 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80 mg (n = 31)
Number of subjects: 92
Study 1914053 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 30)
Number of subjects: 92
Study 6456870 — intervention group
Group type: EXPERIMENTAL
Intervention: Buf-Puf epidermabrasion in combination with benzoyl peroxide (BPO)
Number of subjects: 48
Study 6456870 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide (BPO) alone
Number of subjects: 48
Study 6742394 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.17 mg/kg)
Number of subjects: 34
Study 6742394 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.32 mg/kg)
Number of subjects: 34
Study 6742394 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Diazepam
Number of subjects: 34
Study 30014565 — intervention group
Group type: EXPERIMENTAL
Intervention: Active oral appliance (OA)
Number of subjects: 0
Study 30014565 — intervention group
Group type: COMPARATOR
Intervention: Sham oral appliance (OA)
Number of subjects: 0
Study 27932937 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyzed, high-pH (alkaline) water
Number of subjects: 100
Study 27932937 — intervention group
Group type: COMPARATOR
Intervention: Standard purified water
Number of subjects: 100
Study 25560330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 times a week for 8 weeks, including warm-up, walking at 60% max heart rate, and stretching)
Number of subjects: 53
Study 25560330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 53
Study 25560330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 53
Study 22706631 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (median daily doses of 1,400 IU)
Number of subjects: 173
Study 22706631 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 173
Study 22706631 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a vitamin D supplementation RCT
Number of subjects: 173
Study 22706631 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility criteria for RCT participation
Number of subjects: 173
Study 20547658 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 0
Study 20547658 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) responders
Number of subjects: 0
Study 20547658 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18580847 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5-HTP)
Number of subjects: 18
Study 18580847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16041207 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + LEV + FA
Number of subjects: 855
Study 16041207 — intervention group
Group type: COMPARATOR
Intervention: 5-FU + LEV
Number of subjects: 855
Study 16041207 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + LEV + INF-alpha
Number of subjects: 855
Study 11856687 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler sonography
Number of subjects: 55
Study 11856687 — intervention group
Group type: COMPARATOR
Intervention: Helical CT
Number of subjects: 55
Study 10421299 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 928
Study 9002912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 191
Study 9002912 — intervention group
Group type: COMPARATOR
Intervention: Headgear/Bite Plane
Number of subjects: 191
Study 9002912 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 191
Study 1978873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg plus probenecid 500 mg three times a day for 21 days
Number of subjects: 72
Study 1978873 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice a day for 21 days
Number of subjects: 72
Study 6989482 — intervention group
Group type: EXPERIMENTAL
Intervention: Presymptomatic gonadal radiation immediately after achieving initial marrow remission
Number of subjects: 395
Study 6989482 — intervention group
Group type: COMPARATOR
Intervention: Discontinued therapy after completing three years of continuous complete remission
Number of subjects: 395
Study 6989482 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 395
Study 31345186 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion session delivered to groups of students (not more than 25 at a time) by trained facilitators.
Number of subjects: 0
Study 31345186 — intervention group
Group type: COMPARATOR
Intervention: Control group (students from the control school).
Number of subjects: 0
Study 29485305 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CHECKUP TO GO program (e-CHUG)
Number of subjects: 245
Study 29485305 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 245
Study 26916717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Chemotherapy (ChT)
Number of subjects: 214
Study 26916717 — intervention group
Group type: COMPARATOR
Intervention: Preoperative Chemoradiation (ChRT)
Number of subjects: 214
Study 24787992 — intervention group
Group type: EXPERIMENTAL
Intervention: 33-gauge microneedle
Number of subjects: 20
Study 24787992 — intervention group
Group type: COMPARATOR
Intervention: 30-gauge microneedle
Number of subjects: 20
Study 22252796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg (test treatment)
Number of subjects: 23
Study 22252796 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg administered subcutaneously once daily for 3 days
Number of subjects: 23
Study 22252796 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin pre-treatment
Number of subjects: 23
Study 22252796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 23
Study 22252796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate and Enoxaparin
Number of subjects: 23
Study 19282708 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA cream
Number of subjects: 90
Study 19282708 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 90
Study 19282708 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 90
Study 17621023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive prophylaxis consisting of nimodipine and hydroxyethylstarch, started the day before surgery and continued until the seventh postoperative day.
Number of subjects: 30
Study 17621023 — intervention group
Group type: COMPARATOR
Intervention: No preoperative medication (control group).
Number of subjects: 30
Study 15846258 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin throughout index hospitalization
Number of subjects: 0
Study 15846258 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with unfractionated heparin (UFH) as adjunctive antithrombin therapy
Number of subjects: 0
Study 11598429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy (CBT)
Number of subjects: 108
Study 11598429 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + Fluoxetine (FLX)
Number of subjects: 108
Study 11598429 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + Fluvoxamine (FLV)
Number of subjects: 108
Study 11598429 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLX)
Number of subjects: 108
Study 11598429 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (FLV)
Number of subjects: 108
Study 9161352 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (150 mg daily for 28 days)
Number of subjects: 129
Study 9161352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 7966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention plus bronchodilator
Number of subjects: 5887
Study 7966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention plus placebo
Number of subjects: 5887
Study 7966841 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 5887
Study 7966841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (bronchodilator)
Number of subjects: 5887
Study 3308058 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0
Study 3308058 — intervention group
Group type: COMPARATOR
Intervention: Rigid sigmoidoscopy
Number of subjects: 0
Study 30772854 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP TIC ERP
Number of subjects: 23
Study 30772854 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP TIC HRT
Number of subjects: 23
Study 28285617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee propolis (300 mg three times a day for a total of 900 mg/d)
Number of subjects: 66
Study 28285617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar pills lacking propolis)
Number of subjects: 66
Study 28285617 — intervention group
Group type: EXPERIMENTAL
Intervention: No significant difference reported for other lipids or insulin resistance indices between the two groups.
Number of subjects: 66
Study 25902613 — intervention group
Group type: EXPERIMENTAL
Intervention: WinFood (locally produced complementary foods based on traditional animal-source foods)
Number of subjects: 0
Study 25902613 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 0
Study 24051384 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto‐Trak system during PSV
Number of subjects: 12
Study 24051384 — intervention group
Group type: COMPARATOR
Intervention: Conventional settings (pressure support of 8 cm H2O with flow cycling)
Number of subjects: 12
Study 20571404 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - moderate-intensity aerobic exercise using a bike or treadmill for 45 min, 3-5 times a week, combined with high-intensity inspiratory muscle training for 10 weeks
Number of subjects: 15
Study 20571404 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 15
Study 20571404 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 15
Study 19815116 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 11673
Study 19815116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11673
Study 16729326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 177
Study 16729326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 14592846 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/d vitamin E supplementation
Number of subjects: 16